{"id":32248,"date":"2017-04-12T12:00:00","date_gmt":"2017-04-12T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/"},"modified":"2017-04-12T12:00:00","modified_gmt":"2017-04-12T12:00:00","slug":"nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/","title":{"rendered":"Nouveaux d\u00e9veloppements dans les produits biologiques pour la CRSwNP"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1391 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Rhinologie : D\u00e9bats d&#8217;avenir 2016<\/h2>\n<p>Le Prof. Claire Hopkins (Royaume-Uni) anime cette session pour discuter des nouveaux anticorps monoclonaux pour la rhinosinusite chronique avec polypes nasaux (CRSwNP). Les points abord\u00e9s dans ce d\u00e9bat sont li\u00e9s aux besoins non satisfaits, au d\u00e9fi des nouveaux traitements, aux questions \u00e0 consid\u00e9rer pour le panel et au Dupilumab dans l\u2019inflammation de type 2. <\/p>\n<h3>Pan\u00e9listes<\/h3>\n<p>Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens et Prof. Peter Hellings.<\/p>\n<\/div><\/div>\n<\/p><\/div>\n<p>,  <\/p>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1392 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\">\n<center><iframe width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/D9PBHqQU9GM?rel=0\" title=\"Lecteur vid\u00e9o YouTube\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/center>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rhinologie : D\u00e9bats d&#8217;avenir 2016 Le Prof. Claire Hopkins (Royaume-Uni) anime cette session pour discuter des nouveaux anticorps monoclonaux pour la rhinosinusite chronique avec polypes nasaux (CRSwNP). Les points abord\u00e9s dans ce d\u00e9bat sont li\u00e9s aux besoins non satisfaits, au d\u00e9fi des nouveaux traitements, aux questions \u00e0 consid\u00e9rer pour le panel et au Dupilumab dans l\u2019inflammation de type 2. Pan\u00e9listes Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens et Prof. Peter Hellings. ,<\/p>\n","protected":false},"author":1,"featured_media":32266,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[189],"tags":[175,190,191,192,194],"class_list":["post-32248","news","type-news","status-publish","has-post-thumbnail","hentry","category-rhinology-future-debates","tag-biotherapies","tag-rhinologie","tag-debats","tag-rhinology-future-debates","tag-rhinosinusite-chronique-rsc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nouveaux d\u00e9veloppements dans les produits biologiques pour la CRSwNP - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nouveaux d\u00e9veloppements dans les produits biologiques pour la CRSwNP\" \/>\n<meta property=\"og:description\" content=\"Rhinologie : D\u00e9bats d&#8217;avenir 2016 Le Prof. Claire Hopkins (Royaume-Uni) anime cette session pour discuter des nouveaux anticorps monoclonaux pour la rhinosinusite chronique avec polypes nasaux (CRSwNP). Les points abord\u00e9s dans ce d\u00e9bat sont li\u00e9s aux besoins non satisfaits, au d\u00e9fi des nouveaux traitements, aux questions \u00e0 consid\u00e9rer pour le panel et au Dupilumab dans l\u2019inflammation de type 2. Pan\u00e9listes Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens et Prof. Peter Hellings. ,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\\\/\",\"name\":\"Nouveaux d\u00e9veloppements dans les produits biologiques pour la CRSwNP - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"datePublished\":\"2017-04-12T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/choisissez-votre-parcours\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nouveaux d\u00e9veloppements dans les produits biologiques pour la CRSwNP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nouveaux d\u00e9veloppements dans les produits biologiques pour la CRSwNP - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/","og_locale":"fr_FR","og_type":"article","og_title":"Nouveaux d\u00e9veloppements dans les produits biologiques pour la CRSwNP","og_description":"Rhinologie : D\u00e9bats d&#8217;avenir 2016 Le Prof. Claire Hopkins (Royaume-Uni) anime cette session pour discuter des nouveaux anticorps monoclonaux pour la rhinosinusite chronique avec polypes nasaux (CRSwNP). Les points abord\u00e9s dans ce d\u00e9bat sont li\u00e9s aux besoins non satisfaits, au d\u00e9fi des nouveaux traitements, aux questions \u00e0 consid\u00e9rer pour le panel et au Dupilumab dans l\u2019inflammation de type 2. Pan\u00e9listes Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens et Prof. Peter Hellings. ,","og_url":"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/","url":"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/","name":"Nouveaux d\u00e9veloppements dans les produits biologiques pour la CRSwNP - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","datePublished":"2017-04-12T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/fr\/news\/nouveaux-developpements-dans-les-produits-biologiques-pour-la-crswnp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/fr\/choisissez-votre-parcours\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/fr\/news\/"},{"@type":"ListItem","position":3,"name":"Nouveaux d\u00e9veloppements dans les produits biologiques pour la CRSwNP"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/fr\/#website","url":"https:\/\/www.euforea.org\/fr\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/fr\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/32248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/comments?post=32248"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/32248\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media\/32266"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media?parent=32248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/categories?post=32248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/tags?post=32248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}